12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

12‐month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry

Published:2021-09-13 Issue: Volume: Page:
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmol

Author:

Niedzwiecki Mateusz¹,Hunt Adrian²³^ORCID,Nguyen Vuong³,Mehta Hemal³⁴,Creuzot‐Garcher Catherine⁵,Gabrielle Pierre‐Henry³⁵^ORCID,Guillemin Martin⁵,Fraser‐Bell Samantha³,Arnold Jennifer⁶,McAllister Ian L.⁷,Gillies Mark³,Barthelmes Daniel¹³

Affiliation:

1. Department of Ophthalmology University Hospital Zurich & University of Zurich Zurich Switzerland

2. Department of Ophthalmology Westmead Hospital Westmead NSW Australia

3. The Save Sight Institute Sydney Medical School The University of Sydney Sydney NSW Australia

4. Ophthalmology Department Royal Free London NHS Foundation Trust London UK

5. Department of Ophthalmology Dijon University Hospital Dijon France

6. Marsden Eye Specialists Parramatta NSW Australia

7. Centre for Ophthalmology and Visual Science Lions Eye Institute The University of Western Australia Perth WA Australia

Funder

National Health and Medical Research Council

Royal Australian and New Zealand College of Ophthalmologists

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aos.15014

Reference29 articles.

1. Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders

2. Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion

3. Intravitreal Aflibercept Injection for Macular Edema Secondary to Central Retinal Vein Occlusion: 1-Year Results From the Phase 3 COPERNICUS Study

4.

Real-World Data: Ranibizumab Treatment For Retinal Vein Occlusion In The OCEAN Study

5. Sustained Benefits from Ranibizumab for Macular Edema following Central Retinal Vein Occlusion: Twelve-Month Outcomes of a Phase III Study

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, Safety, and Treatment Burden of Aflibercept 2 mg and Ranibizumab in Retinal Vein Occlusion: A Systematic Review and Meta-analysis;Ophthalmology and Therapy;2024-03-18

2. Initial response and 12-month outcomes after commencing dexamethasone or vascular endothelial growth factor inhibitors for retinal vein occlusion in the FRB registry;Scientific Reports;2024-03-13

3. 12-month outcomes of treatment-naïve retinal vein occlusion initially treated with either dexamethasone implants or vascular endothelial growth factor inhibitors: Data from the Fight Retinal Blindness! registry;2023-08-01

4. Rate and associations of inner retinal thinning in eyes with retinal vein occlusion and regressed macular oedema;Eye;2023-06-30

5. Management of macular oedema due to retinal vein occlusion: An evidence‐based systematic review and meta‐analysis;Clinical & Experimental Ophthalmology;2023-04-14

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3